Zosano Pharma Corporation (ZSANQ) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Fremont, CA, アメリカ. 現CEOは Steven Lo.
ZSANQ を有する 40 名の正社員, に上場 Other OTC.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
